Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0736 · 1 trial · 1 indication
Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean value of the 3 measurements at the 2 timepoints was recorded.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.
| Arm | Type | Description |
|---|---|---|
| High BMI:MK-0736 2mg→Placebo | EXPERIMENTAL | Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B) |
| High BMI:MK-0736 7mg→Placebo | EXPERIMENTAL | Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B) |
| High BMI:MK-0916 6mg→MK-0916 6mg | EXPERIMENTAL | Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| High BMI:Placebo→Placebo | PLACEBO_COMPARATOR | Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| Low BMI:MK-0916 6mg→MK-0916 6mg | EXPERIMENTAL | Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| Low BMI:Placebo→Placebo | PLACEBO_COMPARATOR | Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| Name | Type | Description |
|---|---|---|
| MK0736 | DRUG | - |
| MK0916 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Hypertension systolic blood pressure (SBP) \</= 160mm Hg and diastolic blood pressure (DBP): 90-105mm Hg Exclusion Criteria: * Pre-menopausal women * patients currently taking more than two (2) blood pressure lowering medications * Body Mas Index (BMI)\>40 kg/m2 (morbidly ob...
MK0736 is an investigational small molecule being developed for the treatment of hypertension, or high blood pressure. It is a cardiovascular therapeutic that has been studied in a Phase 2 clinical trial. The drug is not approved and remains in clinical development.
MK0736 is a small molecule designed to treat hypertension, but its specific molecular target has not been disclosed. The drug has been evaluated in a Phase 2 trial for its safety and efficacy in patients with high blood pressure.
MK0736 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company has conducted clinical research on this investigational drug for the treatment of hypertension.
MK0736 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not received FDA approval.
MK0736 has been studied in one completed Phase 2 clinical trial, identified as NCT00274716. This trial, titled 'Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension,' enrolled 249 participants and evaluated the drug's safety and efficacy in treating high blood pressure.
MK0736 is not the same as MK0916. They are separate investigational drugs that were studied together in a single clinical trial, NCT00274716, which evaluated both compounds in patients with hypertension. Each is a distinct small molecule being developed by Merck.